Clinical Trial Update: A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial updates a Phase 1/Phase 2 study evaluating autologous cytokine-induced killer (CIK) cell therapy in hepatocellular carcinoma patients follow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CIK cell therapy (autologous) (cytokine-induced killer cells)

Snippet

Sponsor: Chuan An Biotechnology Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN